By analyzing available paired tumor samples, we put forward a first-defined classification of pre-treatment immune phenotype stratified through CCR8+ Treg cells and CXCL13+ Tex cells to identify those who would benefit more from immunotherapy, which has been verified by multiple large-scale immunotherapy cohorts. This evidence concerns the gene CXCL13 and neoplasm.